Still in silent mode...Merger approved.
Directors now approved with the exception of Dennis Turpin.
Peter Edwards didn't stand for re-election.
New company name now approved.
There was no overview of the past year by Ronnie and Gilles like last year and no plan presented or status update on anything. Still in silent mode. Last year AEZS presented its Q2 financials on August 9.
With the new name approved I guess they will apply immediately to get the name of the stock changed and the symbol. They can now update the website and PR material with the new branding. It would seem a presentation on the new company could take place with the new plan and new branding.
Top-line and full diagnostic trial data is scheduled for Q3 and top-line data could be imminent given the timeline to presentation of adult data previously. That data and a potential licensing deal could greatly affect the forward plan given the potential upfront money, etc.
Then there's all the expected events lined up as has been discussed: bam, bam, bam...
The S&P Biotech ETF is essentially at its 2 1/2 year high.